|Articles|July 29, 2020

Pharmaceutical Executive Global Digest®

Click here to download the August 2020 edition.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report

FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV, Mounjaro to Reduce MACE in Adults with Type 2 Diabetes

Pharmaceutical Executive Global Digest®

Related Content

U.S. Rare Disease Biotech Investing Rises After FDA’s PRV Program Renewal: Report

Legal Risk in a Rumored AstraZeneca-BMS Deal: Q&A with Ron Lanton

FDA Approves Moderna's mRNA-Based Flu Vaccine

Senior Source Denies AstraZeneca and Bristol Myers Deal Talks : Report

CSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in China

Trending on PharmExec

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report

FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV, Mounjaro to Reduce MACE in Adults with Type 2 Diabetes

Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals

M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel

Preventing Batch Loss: The Growing Role of Preventive and Predictive Maintenance